R Murata1, J Overgaard, M R Horsman. 1. Danish Cancer Society, Department of Experimental Clinical Oncology, Aarhus University Hospital. rumi@oncology.dk
Abstract
PURPOSE: To compare the ability of combretastatin A-4 disodium phosphate (CA4DP) and 5,6-dimethylxanthenone-4-acetic acid (DMXAA) to change tissue blood perfusion. MATERIALS AND METHODS: The tissues were a C3H mouse mammary carcinoma and various murine normal tissues, with perfusion measured using the 86RbCl extraction technique. RESULTS: CA4DP (250mg/kg; i.p.) reduced tumour perfusion to 34% of that seen in controls within 1 h of injection. It was maintained at this for at least 6 h, returning to control levels by 24 h. This decrease was dose-dependent. DMXAA (25mg/kg; i.p.) caused a 79% reduction in tumour perfusion 6h after injection; no recovery was observed even after 24 h. DMXAA showed no changes at doses below 10 mg/kg. Both CA4DP and DMXAA increased perfusion in the gut, kidney, bladder and lung, while decreasing splenic perfusion. CA4DP tended to decrease perfusion in muscle, while DMXAA increased liver perfusion. These changes in normal tissue perfusion were generally less than those changes seen in tumours. No significant changes were seen in skin. CONCLUSIONS: CA4DP and DMXAA produced a selective and significant reduction in tumour perfusion, but the pattern of change was different. These results suggest how these vascular targeting drugs should be combined with more conventional therapies.
PURPOSE: To compare the ability of combretastatin A-4 disodium phosphate (CA4DP) and 5,6-dimethylxanthenone-4-acetic acid (DMXAA) to change tissue blood perfusion. MATERIALS AND METHODS: The tissues were a C3H mouse mammary carcinoma and various murine normal tissues, with perfusion measured using the 86RbCl extraction technique. RESULTS:CA4DP (250mg/kg; i.p.) reduced tumour perfusion to 34% of that seen in controls within 1 h of injection. It was maintained at this for at least 6 h, returning to control levels by 24 h. This decrease was dose-dependent. DMXAA (25mg/kg; i.p.) caused a 79% reduction in tumour perfusion 6h after injection; no recovery was observed even after 24 h. DMXAA showed no changes at doses below 10 mg/kg. Both CA4DP and DMXAA increased perfusion in the gut, kidney, bladder and lung, while decreasing splenic perfusion. CA4DP tended to decrease perfusion in muscle, while DMXAA increased liver perfusion. These changes in normal tissue perfusion were generally less than those changes seen in tumours. No significant changes were seen in skin. CONCLUSIONS:CA4DP and DMXAA produced a selective and significant reduction in tumour perfusion, but the pattern of change was different. These results suggest how these vascular targeting drugs should be combined with more conventional therapies.
Authors: Abigail F Welford; Daniela Biziato; Seth B Coffelt; Silvia Nucera; Matthew Fisher; Ferdinando Pucci; Clelia Di Serio; Luigi Naldini; Michele De Palma; Gillian M Tozer; Claire E Lewis Journal: J Clin Invest Date: 2011-04-01 Impact factor: 14.808
Authors: Lotte B Bertelsen; Yuan Yuan Shen; Thomas Nielsen; Hans Stødkilde-Jørgensen; G Kenneth Lloyd; Dietmar W Siemann; Michael R Horsman Journal: Int J Radiat Biol Date: 2011-11 Impact factor: 2.694
Authors: Berenice Venegas; Weiwei Zhu; Nicole B Haloupek; Janet Lee; Elizabeth Zellhart; István P Sugár; Mohammad F Kiani; Parkson Lee-Gau Chong Journal: Biophys J Date: 2012-05-02 Impact factor: 4.033
Authors: Christopher B Pattillo; Berenice Venegas; Fred J Donelson; Luis Del Valle; Linda C Knight; Parkson L-G Chong; Mohammad F Kiani Journal: Pharm Res Date: 2009-01-27 Impact factor: 4.200
Authors: Patricia M LoRusso; Shirish M Gadgeel; Antoinette Wozniak; Alan J Barge; Helen K Jones; Zachary S DelProposto; Pamela A DeLuca; Jeffrey L Evelhoch; Scott A Boerner; Catherine Wheeler Journal: Invest New Drugs Date: 2008-01-25 Impact factor: 3.850
Authors: Philip M Robson; Ananth J Madhuranthakam; Martin P Smith; Maryellen R M Sun; Weiying Dai; Neil M Rofsky; Ivan Pedrosa; David C Alsop Journal: Acad Radiol Date: 2015-10-29 Impact factor: 3.173
Authors: M B Jameson; P I Thompson; B C Baguley; B D Evans; V J Harvey; D J Porter; M R McCrystal; M Small; K Bellenger; L Gumbrell; G W Halbert; P Kestell Journal: Br J Cancer Date: 2003-06-16 Impact factor: 7.640